Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Aprea Therapeutics presented early Phase 1 results for its WEE1 inhibitor APR-1051 at the ASCO 2026 annual meeting, demonstrating signals of clinical activity. The data highlighted partial responses and stable disease in patients with advanced solid tumors across multiple types, with manageable tolerability confirmed across the dosing cohorts.
Key figures
- Drug Name
- APR-1051
- Phase Of Trial
- Phase 1
- Target
- WEE1 inhibitor
- Trial name
- ACESOT-1051
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.